Davidson Capital Management Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Davidson Capital Management Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 111.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,639 shares of the biopharmaceutical company's stock after purchasing an additional 29,826 shares during the quarter. Davidson Capital Management Inc.'s holdings in Halozyme Therapeutics were worth $2,708,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. RPg Family Wealth Advisory LLC purchased a new stake in Halozyme Therapeutics in the third quarter worth about $1,886,000. Segall Bryant & Hamill LLC lifted its stake in Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company's stock worth $20,330,000 after acquiring an additional 49,856 shares during the period. Retirement Systems of Alabama raised its holdings in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. South Street Advisors LLC bought a new position in Halozyme Therapeutics in the third quarter worth about $9,812,000. Finally, Foster & Motley Inc. raised its holdings in Halozyme Therapeutics by 118.6% in the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 12,630 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded down $0.32 during trading hours on Friday, reaching $58.29. The stock had a trading volume of 1,000,407 shares, compared to its average volume of 1,171,441. The stock has a fifty day moving average of $52.50 and a 200 day moving average of $54.50. The stock has a market cap of $7.42 billion, a P/E ratio of 19.30, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52-week low of $35.23 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.